Brehanna Edwards Compares Apixaban or Rivaroxaban in VTE
Brehanna Edwards, PGY-2 Health-System Pharmacy Administration and Leadership Resident at Ascension, shared on LinkedIn:
”Publication Alert
I’m excited to share that our latest work, “Rethinking lead-in strategies: evaluation of full vs. reduced dose factor Xa inhibitors in acute VTE,” has just been published in the Journal of Thrombosis and Thrombolysis.
This multicenter study across 29 hospitals examined whether patients with acute VTE who received prior therapeutic parenteral anticoagulation truly require a full lead-in period of apixaban or rivaroxaban.
Our findings suggest that a reduced lead-in strategy is not associated with increased risk of VTE recurrence or major bleeding, offering important real-world evidence to inform clinical decision-making.
Grateful for the collaborative effort behind this project and excited for the ongoing conversation about optimizing anticoagulation strategies in acute VTE care.”
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering